Schizophrenia As a Risk Factor for Cardiovascular and Metabolic Health Outcomes: a Comparative Risk Assessment

Overview

Journal Epidemiol Psychiatr Sci

Publisher Cambridge University Press

Specialties Psychiatry
Public Health

Date 2023 Feb 9

PMID 36756905

Authors

S Ali

D Santomauro

A J Ferrari

F Charlson

Affiliations

Soon will be listed here.

Abstract

Aims: Cardiometabolic diseases are responsible for the majority of premature deaths in people with schizophrenia. This study aimed to quantify the fatal burden of ischaemic heart disease (IHD), stroke and diabetes attributable to schizophrenia.

Methods: Comparative Risk Assessment methodology from the Global Burden of Disease (GBD) study was used to calculate attributable burden; pooled relative risks (RRs) for IHD, stroke and diabetes were estimated via meta-regression, which were combined with GBD schizophrenia prevalence estimates to calculate the deaths and years of life lost (YLLs) caused by these health outcomes that were attributable to schizophrenia. The proportion of explained all-cause fatal burden and corresponding unexplained burden was also calculated.

Results: The pooled RRs for IHD, stroke and diabetes mortality were 2.36 [95% uncertainty interval (UI) 1.77 to 3.14], 1.86 (95% UI 1.36 to 2.54) and 4.08 (95% UI 3.80 to 4.38) respectively. Schizophrenia was responsible for around 50 000 deaths and almost 1.5 million YLLs globally in 2019 from these health outcomes combined. IHD, stroke and diabetes together explained around 13% of all deaths and almost 11% of all YLLs attributable to schizophrenia, resulting in 320 660 (95% UI 288 299 to 356 517) unexplained deaths and 12 258 690 (95% UI 10 925 426 to 13 713 646) unexplained YLLs.

Conclusions: Quantifying the physical disease burden attributable to schizophrenia provides a means of capturing the substantial excess mortality associated with this disorder within the GBD framework, contributing to an important evidence base for healthcare planning and practice.

Citing Articles

Circulating RBP4 and FABP4 concentrations in patients with chronic schizophrenia are associated with increased epicardial adipose tissue volume and metabolic syndrome.

Lee T, Hsuan C, Lu N, Tsai I, Hsu C, Wang C Eur Arch Psychiatry Clin Neurosci. 2024; .

PMID: 39604670 DOI: 10.1007/s00406-024-01950-5.

Impact of Early Intervention for Early Psychosis on Suicidal Behavior-A Meta-Analysis.

Tahmazov E, Bosse J, Glemain B, Nabbe P, Guillou M, Blachier A Acta Psychiatr Scand. 2024; 151(2):127-141.

PMID: 39601245 PMC: 11695091. DOI: 10.1111/acps.13773.

Schizophrenia and type 2 diabetes risk: a systematic review and meta-analysis.

Dong K, Wang S, Qu C, Zheng K, Sun P Front Endocrinol (Lausanne). 2024; 15:1395771.

PMID: 39324122 PMC: 11422011. DOI: 10.3389/fendo.2024.1395771.

Multimorbidity in Severe Mental Illness as Part of the Neurodevelopmental Continuum: Physical Health-Related Endophenotypes of Schizophrenia-A Narrative Review.

Genkel V, Domozhirova E, Malinina E Brain Sci. 2024; 14(7).

PMID: 39061465 PMC: 11274495. DOI: 10.3390/brainsci14070725.

Anti-spike antibody responses to SARS-CoV-2 mRNA vaccines in people with schizophrenia and schizoaffective disorder.

Nemani K, De Picker L, Dickerson F, Leboyer M, Santacatterina M, Ando F Brain Behav Immun Health. 2024; 38:100802.

PMID: 39021438 PMC: 11252076. DOI: 10.1016/j.bbih.2024.100802.

References

Yung N, Wong C, Chan J, Chen E, Chang W . Excess Mortality and Life-Years Lost in People With Schizophrenia and Other Non-affective Psychoses: An 11-Year Population-Based Cohort Study. Schizophr Bull. 2020; 47(2):474-484. PMC: 7965070. DOI: 10.1093/schbul/sbaa137. View

Galderisi S, De Hert M, Del Prato S, Fagiolini A, Gorwood P, Leucht S . Identification and management of cardiometabolic risk in subjects with schizophrenia spectrum disorders: A Delphi expert consensus study. Eur Psychiatry. 2021; 64(1):e7. PMC: 8057390. DOI: 10.1192/j.eurpsy.2020.115. View

Shor E, Roelfs D, Vang Z . The "Hispanic mortality paradox" revisited: Meta-analysis and meta-regression of life-course differentials in Latin American and Caribbean immigrants' mortality. Soc Sci Med. 2017; 186:20-33. DOI: 10.1016/j.socscimed.2017.05.049. View

Kugathasan P, Laursen T, Grontved S, Jensen S, Aagaard J, Nielsen R . Increased long-term mortality after myocardial infarction in patients with schizophrenia. Schizophr Res. 2018; 199:103-108. DOI: 10.1016/j.schres.2018.03.015. View

Mizuki Y, Sakamoto S, Okahisa Y, Yada Y, Hashimoto N, Takaki M . Mechanisms Underlying the Comorbidity of Schizophrenia and Type 2 Diabetes Mellitus. Int J Neuropsychopharmacol. 2020; 24(5):367-382. PMC: 8130204. DOI: 10.1093/ijnp/pyaa097. View

Pan Y, Yeh L, Chan H, Chang C . Excess mortality and shortened life expectancy in people with major mental illnesses in Taiwan. Epidemiol Psychiatr Sci. 2020; 29:e156. PMC: 7443795. DOI: 10.1017/S2045796020000694. View

Toender A, Vestergaard M, Munk-Olsen T, Larsen J, Kristensen J, Laursen T . Risk of diabetic complications and subsequent mortality among individuals with schizophrenia and diabetes - a population-based register study. Schizophr Res. 2020; 218:99-106. DOI: 10.1016/j.schres.2020.01.024. View

Jones M, Swerdlow A . Bias in the standardized mortality ratio when using general population rates to estimate expected number of deaths. Am J Epidemiol. 1998; 148(10):1012-7. DOI: 10.1093/oxfordjournals.aje.a009567. View

Sarwar N, Gao P, Kondapally Seshasai S, Gobin R, Kaptoge S, Di Angelantonio E . Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010; 375(9733):2215-22. PMC: 2904878. DOI: 10.1016/S0140-6736(10)60484-9. View

10.

Ward M, Druss B . The epidemiology of diabetes in psychotic disorders. Lancet Psychiatry. 2015; 2(5):431-451. DOI: 10.1016/S2215-0366(15)00007-3. View

11.

Whiteford H, Degenhardt L, Rehm J, Baxter A, Ferrari A, Erskine H . Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet. 2013; 382(9904):1575-86. DOI: 10.1016/S0140-6736(13)61611-6. View

12.

Firth J, Siddiqi N, Koyanagi A, Siskind D, Rosenbaum S, Galletly C . The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. Lancet Psychiatry. 2019; 6(8):675-712. DOI: 10.1016/S2215-0366(19)30132-4. View

13.

Zheng Y, Ley S, Hu F . Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2017; 14(2):88-98. DOI: 10.1038/nrendo.2017.151. View

14.

De Hert M, Dekker J, Wood D, Kahl K, Holt R, Moller H . Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of.... Eur Psychiatry. 2009; 24(6):412-24. DOI: 10.1016/j.eurpsy.2009.01.005. View

15.

Osborn D, Levy G, Nazareth I, Petersen I, Islam A, King M . Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Rsearch Database. Arch Gen Psychiatry. 2007; 64(2):242-9. DOI: 10.1001/archpsyc.64.2.242. View

16.

Nordentoft M, Plana-Ripoll O, Laursen T . Cancer and schizophrenia. Curr Opin Psychiatry. 2021; 34(3):260-265. DOI: 10.1097/YCO.0000000000000697. View

17.

. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020; 396(10258):1223-1249. PMC: 7566194. DOI: 10.1016/S0140-6736(20)30752-2. View

18.

Hjorthoj C, Sturup A, McGrath J, Nordentoft M . Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry. 2017; 4(4):295-301. DOI: 10.1016/S2215-0366(17)30078-0. View

19.

Lawrence D, Hancock K, Kisely S . The gap in life expectancy from preventable physical illness in psychiatric patients in Western Australia: retrospective analysis of population based registers. BMJ. 2013; 346:f2539. PMC: 3660620. DOI: 10.1136/bmj.f2539. View

20.

Rodrigues M, Wiener J, Stranges S, Ryan B, Anderson K . The risk of physical multimorbidity in people with psychotic disorders: A systematic review and meta-analysis. J Psychosom Res. 2020; 140:110315. DOI: 10.1016/j.jpsychores.2020.110315. View